TY - JOUR

T1 - Residual viraemia in HIV-1-infected patients with plasma viral load <or=20 copies/ml is associated with increased blood levels of soluble immune activation markers

AU - Ostrowski, S R

AU - Katzenstein, T L

AU - Pedersen, B K

AU - Gerstoft, J

AU - Ullum, H

PY - 2008

Y1 - 2008

N2 - Despite undetectable viral load in conventional assays, probably all human immunodeficiency virus (HIV)-1 infected patients have residual viraemia (RV) detectable by ultra-sensitive assays. To study this issue, this study investigated virologic and immunologic consequences of RV in highly active antiretroviral therapy (HAART)-treated HIV-1-infected patients with plasma HIV-1 RNA or=1 episode with TMA-RV whereas 9 patients had undetectable TMA-RV throughout the study-period. Time-points with TMA-RV and PCR-RV were associated with higher circulating sTNFrII (+0.234 ng/ml, P = 0.030) and beta(2)-microglobulin (+22 nmol/l, P = 0.016) and time-points with PCR-RV were also associated with higher IgA (+0.82 micromol/l, P = 0.035) and CD8-count (+1.18-fold, P = 0.001). Patients with TMA-RV in the study-period had higher HIV-1 RNA pre-HAART (P = 0.032). RV was not associated with proviral-HIV-1-DNA, CD4-count, CD4+HLA-DR+, CD8+HLA-DR+CD38+, CD4+CD45RA-CD45RO+, CD8+CD45RA-CD45RO+, CD4+CD45RA+CD62L+, CD8+CD45RA+CD62L+ T cells, IgG or IgM. In conclusion, RV was associated with increased blood levels of soluble immune activation markers in HAART-treated HIV-1-infected patients. The finding that RV was associated with higher pre-HAART plasma viral load suggests that RV is linked to pre-HAART disease progression.

AB - Despite undetectable viral load in conventional assays, probably all human immunodeficiency virus (HIV)-1 infected patients have residual viraemia (RV) detectable by ultra-sensitive assays. To study this issue, this study investigated virologic and immunologic consequences of RV in highly active antiretroviral therapy (HAART)-treated HIV-1-infected patients with plasma HIV-1 RNA or=1 episode with TMA-RV whereas 9 patients had undetectable TMA-RV throughout the study-period. Time-points with TMA-RV and PCR-RV were associated with higher circulating sTNFrII (+0.234 ng/ml, P = 0.030) and beta(2)-microglobulin (+22 nmol/l, P = 0.016) and time-points with PCR-RV were also associated with higher IgA (+0.82 micromol/l, P = 0.035) and CD8-count (+1.18-fold, P = 0.001). Patients with TMA-RV in the study-period had higher HIV-1 RNA pre-HAART (P = 0.032). RV was not associated with proviral-HIV-1-DNA, CD4-count, CD4+HLA-DR+, CD8+HLA-DR+CD38+, CD4+CD45RA-CD45RO+, CD8+CD45RA-CD45RO+, CD4+CD45RA+CD62L+, CD8+CD45RA+CD62L+ T cells, IgG or IgM. In conclusion, RV was associated with increased blood levels of soluble immune activation markers in HAART-treated HIV-1-infected patients. The finding that RV was associated with higher pre-HAART plasma viral load suggests that RV is linked to pre-HAART disease progression.

KW - Adult

KW - Aged

KW - Anti-HIV Agents

KW - Antiretroviral Therapy, Highly Active

KW - CD4 Lymphocyte Count

KW - Disease Progression

KW - Female

KW - Flow Cytometry

KW - HIV Infections

KW - HIV-1

KW - Humans

KW - Immunoglobulins

KW - Male

KW - Middle Aged

KW - Models, Statistical

KW - Prospective Studies

KW - RNA, Viral

KW - Receptors, Tumor Necrosis Factor, Type II

KW - Reverse Transcriptase Polymerase Chain Reaction

KW - Viral Load

KW - Viremia

KW - beta 2-Microglobulin

U2 - 10.1111/j.1365-3083.2008.02184.x

DO - 10.1111/j.1365-3083.2008.02184.x

M3 - Journal article

C2 - 19055701

VL - 68

SP - 652

EP - 660

JO - Scandinavian Journal of Immunology, Supplement

JF - Scandinavian Journal of Immunology, Supplement

SN - 0301-6323

IS - 6

ER -